+ 0.74
+ 0.42%

Regulators Approve GW Pharmaceuticals' Cannabis-based Epidyolex In Australia

September 23, 2020 10:34 am
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More

Epidyolex, the first FDA approved CBD medicine for severe epilepsy in children, received Australian Therapeutic Goods Administration approval.

GW Pharmaceuticals plc (NASDAQ:GWPHconfirmed Wednesday that TGA authorized the medicine to treat Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age and older.

To bring medicine to Australian patients, GW teamed up with Chiesi Australia.

The UK-based global biopharmaceutical company also collaborated with Australia’s Pharmaceutical Benefits Advisory Committee to obtain reimbursement for the medicine via listing on the Pharmaceutical Benefits Scheme.

The medicine was also approved by the US Food and Drug Administration in 2018, by European Commission a year later and, just this month, approved in Scotland

“This marks our third global regulatory approval and is another important step for GW and the patients we are here to support,” GW COO Chris Tovey said. 

Chiesi Australia’s General Manager, Chris Rossidis, said that this is an “important step forward for the management of LGS and Dravet syndrome,” highlighting that they are working on achieving “greater access to this medicine as soon as possible.”

The FDA recently gave a green light for expanded indications for the drug by adding management of seizures related to tuberous sclerosis complex.

Besides label expansion, the US regulatory body also expanded the age range in all approved indications, including patients of one year of age and older.

Courtesy image

Related Articles

Cannabis Stock Gainers And Losers From October 30, 2020

GAINERS: Golden Leaf Holdings (OTCQB: GLDFF) shares closed up 14.71% at $0.02 read more

Green Thumb Industries Sells $79M Stake To Undisclosed Investor

Green Thumb Industries (CSE: GTI) (OTCQX: GTBIF) confirmed Friday that an undisclosed institutional investor bought 5.5 million subordinated voting shares in the company for $79 million. read more

A United Nations Vote On Cannabis Recommendations Would Be Historic

The United Nations Commission on Narcotic Drugs (CND) is slated to vote on cannabis recommendations from the World Health Organization (WHO) on Dec. 2. read more

Harvest Health Opens 8th Pennsylvania Store In King of Prussia

Vertically integrated cannabis company Harvest Health & Recreation Inc. (CSE: HARV) (OTCQX: HRVSF) is cutting the ribbon on its eight store in Pennsylvania. read more

IntelGenx And Heritage Cannabis Holdings Partner To Produce CBD Filmstrip Products

IntelGenx Corp. (TSXV: IGX) (OTCQB: IGXT) has partnered with Canadian medical cannabis producer Heritage Cannabis Holdings Corp. to produce filmstrip products containing CBD. read more